Salut, Covid-19, Vacunes

EpiVacCorona

The second vaccine developed in Russia is EpiVacCorona. There is still little information about this vaccine, which has already been approved by the government, but as of 19 March was not yet being used to immunise the population. 

Manufactured by the State Research Center of Virology and Biotechnology VECTOR, EpiVacCorona is a vaccine based on synthetic peptides. Its composition includes a synthetic version of SARS-CoV-2 protein fragments (or peptides) to trigger the immune response in the body. The phase III clinical trial began in November 2020 and involved about 3,000 volunteers from Russia. The results have not yet been published, but officials assured that it offered 100% efficacy during phases I and II. It consists of two doses, administered over 21 to 28 days

It is not known at this stage whether it causes adverse reactions and there is no information on the temperature at which it should be stored.

We have a favor to ask you! A small favor for a great cause.

3 out of 4 young people lack the critical training to surf the Internet.

That is why we have launched a crowdfunding to develop the Desfake digital platform, to share educational tools with secondary education teachers.

The good news: Barcelona City Council will double each contribution to our campaign, which also deducts personal income tax. In other words, with a little help from you, you can make a huge difference.

Will you help us? Make your contribution here!


Aquest article és part del projecte "Les Mentides Amenacen la Salut", el primer portal de fact-checking de rumors sobre la covid-19 de Catalunya.

Alguna cosa que t’han enviat o has vist t’ha fet soroll?

Envia’ns un Whatsapp per poder verificar-ho o escriu a [email protected]